Targeted Market Specialize outreach to breast cancer screening programs, hospitals, and imaging centers that handle dense breast populations and may benefit from LumaGEM MBI's higher sensitivity and lower false positives.

Strategic Partnerships Highlight opportunities with radiology equipment distributors and service providers (e.g., hospitals and medical device distributors) to leverage Gamma Medica-Ideas' dual-head DDCGI technology through existing sales channels.

Regulatory Advantage Position the company as a FDA-cleared, solid-state imaging option, emphasizing regulatory clearance and robustness to accelerate procurement conversations with institutions seeking innovative molecular imaging.

Growth Narrative Leverage the recent funding and modest revenue scale to pursue co-sell or partnership deals with larger healthcare tech players, offering a path to scale via OEM or integration collaborations.

Evidence of Value Use performance metrics (high sensitivity/specificity and reduced false positives in dense breast tissue) as a differentiator in RFPs and value-based procurement discussions to drive consideration among decision makers.